Medtronic Cardiac Ablation Solutions
Trial Pipeline
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
NCT07308847
SPHERE Per-AF Post-Approval Study
NCT06858306
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
NCT06703489
PULSED AF Post-Approval Study
NCT06578104
STOP AF First Post-Approval Study
NCT05227053
STOP Persistent AF PAS
NCT05005949
Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
NCT04198701
ArcticLine Feasibility Study
NCT03604263
STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation
NCT03118518
STOP Persistent AF
NCT03012841
Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)
NCT01456949
Study for Atrial Fibrillation Reduction (SAFARI)
NCT00267137
What the Pipeline for Medtronic Cardiac Ablation Solutions Shows
According to the ClinicalTrials.gov registry, Medtronic Cardiac Ablation Solutions is linked to 12 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 42% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 50% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Medtronic Cardiac Ablation Solutions reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Medtronic Cardiac Ablation Solutions is Atrial Fibrillation with 5 linked trials, and 8 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.